These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 28081149)
1. Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax. Yadava A; Waters NC PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005164. PubMed ID: 28081149 [No Abstract] [Full Text] [Related]
2. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Atcheson E; Bauza K; Salman AM; Alves E; Blight J; Viveros-Sandoval ME; Janse CJ; Khan SM; Hill AVS; Reyes-Sandoval A Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986894 [TBL] [Abstract][Full Text] [Related]
3. Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G; del Portillo HA Mem Inst Oswaldo Cruz; 1994; 89 Suppl 2():81-4. PubMed ID: 7565138 [No Abstract] [Full Text] [Related]
4. Towards a vaccine against Plasmodium vivax malaria. Beeson JG; Crabb BS PLoS Med; 2007 Dec; 4(12):e350. PubMed ID: 18092888 [TBL] [Abstract][Full Text] [Related]
14. An update on the search for a Plasmodium vivax vaccine. Herrera S; Corradin G; Arévalo-Herrera M Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Lumsden JM; Pichyangkul S; Srichairatanakul U; Yongvanitchit K; Limsalakpetch A; Nurmukhambetova S; Klein J; Bertholet S; Vedvick TS; Reed SG; Sattabongkot J; Bennett JW; Polhemus ME; Ockenhouse CF; Howard RF; Yadava A Infect Immun; 2011 Sep; 79(9):3492-500. PubMed ID: 21690242 [TBL] [Abstract][Full Text] [Related]
16. Human antibodies against DBP. Richards JS; Ramsland PA Nat Microbiol; 2019 Sep; 4(9):1428-1429. PubMed ID: 31439930 [No Abstract] [Full Text] [Related]
17. Live attenuated pre-erythrocytic malaria vaccines. Keitany GJ; Vignali M; Wang R Hum Vaccin Immunother; 2014; 10(10):2903-9. PubMed ID: 25483648 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294 [TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Arévalo-Herrera M; Soto L; Perlaza BL; Céspedes N; Vera O; Lenis AM; Bonelo A; Corradin G; Herrera S Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):35-42. PubMed ID: 21292876 [TBL] [Abstract][Full Text] [Related]
20. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody. Rawlinson TA; Barber NM; Mohring F; Cho JS; Kosaisavee V; Gérard SF; Alanine DGW; Labbé GM; Elias SC; Silk SE; Quinkert D; Jin J; Marshall JM; Payne RO; Minassian AM; Russell B; Rénia L; Nosten FH; Moon RW; Higgins MK; Draper SJ Nat Microbiol; 2019 Sep; 4(9):1497-1507. PubMed ID: 31133755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]